Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Jongen

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Patient Preference and Adherence|May 14, 2016
Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatmentLeo H Visser, Marco A Heerings, Peter J Jongen, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|July 23, 2017
Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scalingIngrid E H Kremer, Silvia M A A Evers, Peter J Jongen, et al.
Health and Quality of Life Outcomes|November 17, 2010
Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre studyPeter J Jongen, Dirk Lehnick, Evert Sanders, et al.
JMIR Mhealth and Uhealth|October 5, 2020
Symbol Digit Modalities Test Variant in a Smartphone App for Persons With Multiple Sclerosis: Validation StudyPim van Oirschot, Marco Heerings, Karine Wendrich, et al.
BMC Neurology|June 9, 2011
Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive batteryChris Edgar, Peter J Jongen, Evert Sanders, et al.
Plos One|November 5, 2016
Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst ScalingIngrid E H Kremer, Silvia M A A Evers, Peter J Jongen, et al.
The Lancet. Neurology|June 15, 2010
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trialMads Ravnborg, Per Soelberg Sørensen, Magnus Andersson, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosisAnthony L Traboulsee, Peter Cornelisseª, Magnhild Sandberg-Wollheim, et al.
Journal of Neurochemistry|June 11, 2013
Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosisMyrthe Rouwette, Jean-Paul Noben, Jack Van Horssen, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 11, 2020
Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition ModelIngrid E H Kremer, Mickael Hiligsmann, Josh Carlson, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Patient Preference and Adherence|May 14, 2016
Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatmentLeo H Visser, Marco A Heerings, Peter J Jongen, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|July 23, 2017
Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scalingIngrid E H Kremer, Silvia M A A Evers, Peter J Jongen, et al.
Health and Quality of Life Outcomes|November 17, 2010
Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre studyPeter J Jongen, Dirk Lehnick, Evert Sanders, et al.
JMIR Mhealth and Uhealth|October 5, 2020
Symbol Digit Modalities Test Variant in a Smartphone App for Persons With Multiple Sclerosis: Validation StudyPim van Oirschot, Marco Heerings, Karine Wendrich, et al.
BMC Neurology|June 9, 2011
Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive batteryChris Edgar, Peter J Jongen, Evert Sanders, et al.
Plos One|November 5, 2016
Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst ScalingIngrid E H Kremer, Silvia M A A Evers, Peter J Jongen, et al.
The Lancet. Neurology|June 15, 2010
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trialMads Ravnborg, Per Soelberg Sørensen, Magnus Andersson, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosisAnthony L Traboulsee, Peter Cornelisseª, Magnhild Sandberg-Wollheim, et al.
Journal of Neurochemistry|June 11, 2013
Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosisMyrthe Rouwette, Jean-Paul Noben, Jack Van Horssen, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 11, 2020
Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition ModelIngrid E H Kremer, Mickael Hiligsmann, Josh Carlson, et al.
Pageof 2